Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

10-11-2017 | Breast cancer | Article

The Shifting Paradigm for Breast Cancer Surgery in Patients Undergoing Neoadjuvant Chemotherapy

Journal: Annals of Surgical Oncology

Authors: Olga Kantor, MD, MS, Gaurav Ajmani, MHS, Chi-Hsiung Wang, PhD, Avisek Datta, MS, Katharine Yao, MD, FACS

Publisher: Springer International Publishing

Login to get access

Abstract

Introduction

Surgical therapy for newly diagnosed breast cancer has changed over the past decade, but these trends have not been well documented in patients undergoing neoadjuvant therapy (NAC).

Methods

In a retrospective cohort study of the National Cancer Database (NCDB), we selected 285,514 women with clinical stage I–III breast cancer who underwent NAC or adjuvant therapy (AC) from 2006 to 2014. Breast-conserving surgery (BCS), unilateral mastectomy (UM), and bilateral mastectomy (BM) rates were compared between patients undergoing NAC and AC.

Results

Of 285,514 women, 68,850 (24.1%) underwent NAC. Of NAC patients, 18,158 (26.4%) underwent BM and 27,349 (39.7%) BCS compared with 31,886 (14.7%) and 120,626 (55.7%) AC patients, respectively. From 2006 to 2014, BM increased from 16.1 to 28.8% (p < 0.001) for NAC and from 7.4 to 17.5% (p < 0.001) for AC. After adjusting for patient, tumor, and facility factors, NAC patients were 1.50 times [odds ratio (OR) 1.50, confidence interval (CI) 1.42–1.51] more likely to undergo BM then AC patients. The difference in BM rates between patients receiving NAC versus AC varied significantly by cT classification. This difference was the greatest among cT1 tumors between NAC and AC (31.7 vs. 13.0%, p < 0.001), followed by cT2 tumors (24.1 vs. 16.6%, p < 0.001) and cT3 tumors (24.3 vs. 22.3%).

Conclusions and Relevance

More NAC patients are undergoing BM while fewer are undergoing BCS compared with patients undergoing AC. This trend is particularly striking for those patients with smaller tumors who would otherwise be candidates for BCS.
Literature
1.
Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I–III breast cancer in the United States. Cancer. 2015;121(15):2544–2552.CrossRefPubMed
2.
von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–756.CrossRef
3.
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–785.CrossRefPubMed
4.
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–1461.CrossRefPubMedPubMedCentral
5.
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2014; http://​www.​fda.​gov/​downloads/​drugs/​guidancecomplian​ceregulatoryinfo​rmation/​guidances/​ucm305501.​pdf. Accessed February 13, 2017.
6.
NIH consensus conference. Treatment of early-stage breast cancer. JAMA. 1991;265(3):391–395.CrossRef
7.
King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158–2164.CrossRefPubMed
8.
Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150(1):9–16.CrossRefPubMed
9.
Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203–5209.CrossRefPubMed
10.
Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27(9):1362–1367.CrossRefPubMed
11.
Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol. 2010;17(10):2554–2562.CrossRefPubMed
12.
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–2685.CrossRefPubMed
13.
Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II–III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262(3):434-439. discussion 438-439.CrossRefPubMedPubMedCentral
14.
Killelea BK, Long JB, Chagpar AB, et al. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. Breast Cancer Res Treatment. 2013;141(1):155–163.CrossRef
15.
McGuire KP, Hwang ES, Cantor A, et al. Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. Ann Surg Oncol. 2015;22(1):75–81.CrossRefPubMed
16.
Jagsi R, Hawley ST, Griffith KA, et al. Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. JAMA Surg. 2017;152(3):274–282.CrossRefPubMed
17.
Covelli AM, Baxter NN, Fitch MI, McCready DR, Wright FC. ‘Taking control of cancer’: understanding women’s choice for mastectomy. Ann Surg Oncol. 2015;22(2):383–391.CrossRefPubMed
18.
Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013;159(6):373–381.CrossRefPubMedPubMedCentral
19.
Yao K, Belkora J, Bedrosian I, et al. Impact of an in-visit decision aid on patient knowledge about contralateral prophylactic mastectomy: a pilot study. Ann Surg Oncol. 2017;24(1):91–99.CrossRefPubMed
20.
Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY. Comparison of commission on cancer-approved and –nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009;27:4177–81.CrossRefPubMed
21.
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. Chicago, IL: Springer; 2010.CrossRef
22.
US Census. Statistical Groupings of States and Counties. 2010; http://​www.​census.​gov/​geo/​reference/​pdfs/​GARM/​Ch6GARM.​pdf. Accessed February 13, 2017.
23.
De Los Santos JF, Cantor A, Amos KD, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013;119(10):1776–1783.CrossRefPubMedPubMedCentral
24.
Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940–1949.CrossRefPubMed
25.
Krammer J, Pinker-Domenig K, Robson ME, et al. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treatment. 2017;163(3):565–571.CrossRef
26.
Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282–4288.CrossRefPubMed
27.
van der Kolk DM, de Bock GH, Leegte BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treatment. 2010;124(3):643–651.CrossRef
28.
Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328–2335.CrossRefPubMed
29.
Wang F, Amara D, Peled AW, et al. Negative genetic testing does not deter contralateral prophylactic mastectomy in younger patients with greater family histories of breast cancer. Ann Surg Oncol. 2015;22(10):3338–3345.CrossRefPubMed
30.
Hawley ST JR, Morrow M, Katz SJ. Correlates of contralateral prophylactic mastectomy in a population based sample. J Clin Oncol. 2011;29:6010.CrossRef
31.
Hunt KK, Euhus DM, Boughey JC, et al. Society of surgical oncology breast disease working group statement on prophylactic (risk-reducing) mastectomy. Ann Surg Oncol. 2017;24(2):375–397.CrossRefPubMed
32.
Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016;23(10):3100-3105.CrossRefPubMedPubMedCentral
33.
NIH Consensus Development Conference statement on the treatment of early-stage breast cancer. Oncology (Williston Park). 1991;5(2):120–124.
Image Credits